Viral complications after renal allotransplantation  by Metodiev, Kr. et al.
Abstracts of the 12th ISIIH 2S37 
, r  
Fever 37 
Bloodstream infections (BC+) 9 
Use of vancomycin (VAN)/ 231 
amphotericin B (AMB) 4 
Days on antibiotics, mean (*SD) 14 (+-9) 
No. of readmissions at D+60 9 
Death 2 
No IC 
fn=43) P 
35 0.77 
6 0.57 
181 0.391 
4 0.99 
12 (a5) 0.51 
4 0.09 
1 0.99 
Conclusion: Keeping a previously placed IC did not 
seem to increase morbidity in this population of APSCT 
recipients. 
Analysis of risk factors for aerobic gram negative 
bacilli (AGNB) bacteremia (B) in bematopoietic stem 
cell transplant (HSCT) recipients (R): is there a high 
risk population? 
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Aim: Identification in HSCT R of a high risk population 
to develop AGNB B, who may benefit from anti- 
microbial preemptive therapy. 
Material and methods: A retrospective study conducted 
from January 1997 to December 2001; 258 HSCT R were 
included from the beginning of chemotherapy until 
neutropenia was resolved. We studied 231 febrile 
episodes, excluding B due to other microorganisms : 35 
with and 196 without B, which were evaluated analyzing 
age, sex, underlying disease, type of HSCT, grade of oral 
and gastrointestinal(G1) mucositis, abdominal and/or 
anal clinical site of infection, ICU requirement, and 
procedure-related mortality(PRM). 
Results: The prevalence of B was 13.5% (35/258). We 
found significant differences in : grade of GI mucositis 
manifested by diarrhea ~100Oml/day: 13/35 vs. 37/196, 
p=O.O02, RR=2.14, IC95%=1.16-3.94; abdominal/anal 
clinical site: 12/35 vs. 12/196,p=O.OOl,RR=4.50, IC 95% 
2.58-7.84; ICU requirement: 14/35 vs. 291196, p=O.OOl, 
RR=2.91, IC95% =1.62-5.26. The presence of diarrhea 
2 lOOOml/day, predicted B due to AGNB with sensitivity 
(S)=37% and specificity(Sp)=81% with a positive pre- 
dictive value (PPV) =25 % and negative predictive value 
(NPV)=87%; the presence of abdominal/anal site pre- 
dictedB withS=34%,Sp=93%,PPV=46% andNPV= 
88%. 
VRE infections have become a significant cause of 
morbidity and mortality among pt undergoing OLT. 
However, it is not known if VRE colonization pre-OLT 
is associated with worse outcomes. All adult pt listed for 
OLT at the University of Michigan from 1100 to 3102 
were eligible for study. Underlying illness, antimicrobial 
use, hospital stay, severity of liver disease, and other 
clinical data were gathered; rectal swabs for VRE were 
done at 4-6 month intervals pre-OLT. VRE cultures 
were repeated prior to transplant and every 5 days 
during the post-OLT hospitalization. Intra-operative 
bile cultures for VRE were obtained at OLT. Pt were 
followed for 2 months post-OLT to assess outcomes. 
Among 360 pt in the study, 42 (12%) were colonized 
with VRE prior to OLT. Of these 42, 64% were men; 
hepatitis C was the most common underlying diagnosis 
(26 %), and 12% had received a prior OLT. Colonized 
pt spent a mean of 14?14 days in hospital and received 
a mean of 46+-68 days of antimicrobial therapy during 
the previous 6 months. Of the 42 colonized pt, 11 died 
prior to OLT, 16 remain on the waiting list, 15 underwent 
OLT. Among these 15, 3 developed VRE-related 
infections post-OLT and 2 pt died, 1 secondary to VRE 
sepsis and endocarditis. 89 pt who were not colonized 
with VRE received an OLT; 9 (10%) died and 16 (18%) 
became colonized with VRE prior to discharge from 
hospital. Two of the 16 developed serious VRE-related 
infections that contributed to their deaths. 
VRE colonization is prevalent among pt awaiting 
OLT. Among 15 VRE colonized pt undergoing OLT, 3 
developed VRE-related infections; 2 of 16 pt who 
acquired VRE post-OLT developed VRE-related 
infections. VRE colonization prior to OLT does not 
appear to increase mortality. 
Comments: (1) The presence of diarrhea z lOOOml/day 
increased B risk by two times and was predictive in 1 of 
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5 episodes of fever with high NPV. (2) The presence of 
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abdominal/anal site of infection increased the risk of B 
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of fever ( PPV 46%). (3) B due to AGNB increased ICU 
requirements nearly 3 times and doubled the risk of 
mortality-related procedure. 
Conclusion: We propose the use of empirical antibiotic 
preemptive therapy in neutropenic HSCT R with 
diarrhea 2 lOOOml/day or with abdominal/anal clinical 
site of infection, despite the presence of fever. 
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It is well known that two major complications are mani- 
fested after any solid organ transplantation: rejection 
crisis due to immune conflict and infectious processes 
due to various agents (bacterial, viral, fungal). The 
question of exact and precise differentiation leads to 
adequate therapeutic decisions, because the proper 
immunosuppression would tend to preserve the rejected 
organ, but from the other hand, would interfere with the 
infection, if clinically manifested. The prediction of any 
of both complications gives a chance to overcome the 
clinical problem before its full development. Our model 
of a dynamic immunologic monitoring allows a precise 
differentiation and prognosis of the forthcoming com- 
plications after renal allotransplantation. The individuals 
studied are 54 recipients of renal allografts plus a control 
group of 24 hemodialysis patients, altogether 78. The 
methods included in this study are immunologic and 
microbiologic. The immunologic monitoring (T-helper 
and T-suppressor test and ratio-index; RBT, macrophage 
activity NBT-test, enzymatic activity SDH, alpha- 
GPDH, LDH; CIC; complement C3; NK-cell activity; 
warm and cold anti-T and anti-B antibodies; thin-needle 
aspiration biopsy morphologic analysis) is dynamically 
performed before and after transplantation and is applied 
very successfully for differentiation and prediction of 
both, rejection and infections (see our previous studies). 
The microbiologic analysis includes both, bacterial 
and viral, examinations to find out the actual cause of 
the infectious process. It is established that the following 
bacteria could be etiologic factors postoperatively: 
E. coli, Enterobacter, S. aureus, S. epidermidis, Pseudo- 
monas, Proteus, Klebsiella, E. faecalis, and Acinetobacter. 
As the bacterial origin of the infections is not our aim in 
this study, we neglect those agents: 65% of all post- 
transplantation infections. The virology analysis shows 
that 32% of all infections postoperatively are with viral 
origin: CMV, Hep. B and Hep. C virus, influenza virus, 
HIV The other 3% of the infections are from fungal 
origin (also out of our research plans at the moment). 
The results show that 21 cases (32%) are with viral 
infections: CMV - 8 (38%), HepB - 4 (19%), HepC -3 
(14%), Influenza - 5 (24%), HIV - 1 (5%), but 4 cases 
have a mixed infection: CMV+Influenza (2), CMV+ 
Hep+HIV (l), Influenza+Hep (1). The duration of the 
viral complications is 1.5 times longer than the bacterial 
ones. Two of the recipients with viral infections have a 
lethal issue: 1 with HIV (mixed with CMV+Hep) and 
1 with CMV (mixed with Influenza). Over 80% of all 
viral complications are clinically manifested in patients 
treated with cyclosporine and under 20% are in recipients 
without current cyclosporine therapy. The hemodialysis 
patients (24) show a prevalence of Hep-infections and 
2/3 of the cases are HepC. The immunologic monitoring 
definitely helps to predict and differentiate the immune 
conflict and rejection, as one of the two major com- 
plications after renal allotransplantation, and the 
infection, as a second one. From the other hand, the viral 
processes and the manifested immunodefficiency, alone 
or in combination, require a thorough analysis, exact 
diagnosis and individual therapeutic scheme. 
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Measles vaccination has been recommended after the 
second year following BMT, for patients not receiving 
immunosuppression. During a measles outbreak that 
irrupted in the city of SBo Paulo in 1997, we started 
measles vaccination for all patients after the first year of 
transplantation and conducted a prospective trial to 
evaluate the safety, effectiveness and sustained 
immunity after early measles vaccination. Patients 
received attenuated virus measles vaccination on day 
+365. Measles antibodies were detected by ELISA in 
serum samples taken on months 0,2,6,12 and 24 after 
vaccination. Thirty seven BMT recipients (5 ABMT, 
32 ALO) were evaluated. No severe or moderate 
adverse reactions was noted. Nine patients (24.3%) were 
susceptible (IgG 2 100 mUI/mL) at vaccination and all 
of them seroconverted. In patients considered immune 
at vaccination, a four fold rise in IgG titers was observed 
in only one of 24 patients (4.1%) with IgG ~200 
mUI/mL as compared to three of 4 patients (75%) with 
lOOcIgG<200 mUI/mL (p=O.O012), supporting that 
higher titers avoid wild or vaccine virus replication. 
Survival analysis showed a 96.4%, 86% and 60.2% 
probabilities of sustained measles immunity at 12,18 and 
24 months after early measles vaccination, respectively. 
Patients with IgG titers between 200 and 500 mUI/mL 
at vaccination were less likely to retain measles 
immunity 12 months after vacciantion as compared to 
those with IgG titers 2500 mUI/mL (p=O.Ol). The 
former patients should be screened more frequently for 
measles antibodies during follow-up. We concluded that 
measles vaccination on day +365 is safe and effective in 
BMT recipients and can be recommended in countries 
that did not achieved measles elimination. Booster doses 
of measles vaccine should be recommended only in 
patients with IgG titers <200mUI/mL. 
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